Membrane transporters as mediators of cisplatin side-effects

Anticancer Research

Volumn 34, Issue 1, 2014, Pages 547-550

  Ciarimboli, Giuliano ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Cisplatin; Ctr2; MATE1; Membrane transporters; OCT2; Review; Toxicities; Transporters

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CARRIER PROTEIN; CIMETIDINE; CISPLATIN; COPPER EXPORTING ADENOSINE TRIPHOSPHATASE; COPPER TRANSPORTER 1; COPPER TRANSPORTER 2; CREATININE; MULTIDRUG EXTRUSION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; P TYPE COPPER TRANSPORTING ATP7A; P TYPE COPPER TRANSPORTING ATP7B; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CATION TRANSPORT PROTEIN; PROTECTIVE AGENT;

ACUTE TOXICITY; CANCER CHEMOTHERAPY; CELL TRANSPORT; COCHLEA; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DRUG TOXICITY; GLOMERULUS FILTRATION RATE; HAIR CELL; HUMAN; IN VITRO STUDY; KIDNEY PLASMA FLOW; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PROTEIN EXPRESSION; RENAL PROTECTION; SPINAL GANGLION; STRIA VASCULARIS; ADVERSE DRUG REACTION; ANIMAL; CTR2; MATE1; MEMBRANE TRANSPORTERS; METABOLISM; MOUSE; NEOPLASM; OCT2; REVIEW; TOXICITIES; TRANSPORT AT THE CELLULAR LEVEL; TRANSPORTERS;

CISPLATIN; CTR2; MATE1; MEMBRANE TRANSPORTERS; OCT2; REVIEW; TOXICITIES; TRANSPORTERS;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CATION TRANSPORT PROTEINS; CISPLATIN; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MEMBRANE TRANSPORT PROTEINS; MICE; NEOPLASMS; PROTECTIVE AGENTS;

EID: 84897022237     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Ciarimboli G: Role of organic cation transporters in drug-induced toxicity. Expert Opin Drug Metab Toxicol 7: 159-174, 2011.
2. Zhou SF: Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38: 802-832, 2008.
3. Rabik CA and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23, 2007.
4. Fillastre JP and Raguenez-Viotte G: Cisplatin nephrotoxicity. Toxicol Lett 46: 163-175, 1989.
5. Daugaard G: Cisplatin nephrotoxicity: experimental and clinical studies. Dan Med Bull 37: 1-12, 1990.
6. Pabla N and Dong Z: Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73: 994-1007, 2008.
7. Litterst CL, Gram TE, Dedrick RL, LeRoy AF and Guarino AM: Distribution and disposition of platinum following intravenous administration of cis-diamminedichloroplatinum(II) (NSC 119875) to dogs. Cancer Res 36: 2340-2344, 1976.
8. Dobyan DC, Levi J, Jacobs C, Kosek J and Weiner MW: Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther 213: 551-556, 1980.
9. Rybak LP: Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otolaryngol Head Neck Surg 15: 364-369, 2007.
10. Skinner R: Best practice in assessing ototoxicity in children with cancer. Europ J Cancer 40: 2352-2354, 2004.
11. Albers JW, Chaudhry V, Cavaletti G, and Donehower RC: Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev CD005228, 2011.
12. Meijer C, de Vries EG, Marmiroli P, Tredici G, Frattola L and Cavaletti G: Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology 20: 883-887, 1999.
13. Ishida S, Lee J, Thiele DJ and Herskowitz I: Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 99: 14298-14302, 2002.
14. Blair BG, Larson CA, Safaei R and Howell SB: Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Clin Cancer Res 15: 4312-4321, 2009.
15. Samimi G, Katano K, Holzer AK, Safaei R and Howell SB: Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Mol Pharmacol 66: 25-32, 2004.
16. Ciarimboli G, Ludwig T, Lang D, Pavenstädt H, Koepsell H, Piechota HJ, Haier J, Jaehde U, Zisowsky J and Schlatter E: Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 167: 1477-1484, 2005.
17. Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B, Pavenstädt H, Lanvers-Kaminsky C, Am Zehnhoff-Dinnesen A, Schinkel AH, Koepsell H, Jurgens H and Schlatter E: Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol 176: 1169-1180, 2010.
18. Yonezawa A, Masuda S, Yokoo S, Katsura T and Inui K: Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 319: 879-886, 2006.
19. Nakamura T, Yonezawa A, Hashimoto S, Katsura T and Inui KI: Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem Pharmacol 80: 1762-1767, 2010.
20. Ciarimboli G: Organic cation transporters. Xenobiotica 38: 936-971, 2008.
21. Urakami Y, Nakamura N, Takahashi K, Okuda M, Saito H, Hashimoto Y and Inui K: Gender differences in expression of organic cation transporter OCT2 in rat kidney. FEBS Lett 461: 339-342, 1999.
22. Meetam P, Srimaroeng C, Soodvilai S and Chatsudthipong V: Regulatory role of testosterone in organic cation transport: in vivo and in vitro studies. Biol Pharm Bull 32: 982-987, 2009.
23. Yonezawa A, Masuda S, Nishihara K, Yano I, Katsura T and Inui K: Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem Pharmacol 70: 1823-1831, 2005.
24. Filipski KK, Loos WJ, Verweij J and Sparreboom A: Interaction of Cisplatin with the human organic cation transporter 2. Clin Cancer Res 14: 3875-3880, 2008.
25. Jonker JW, Wagenaar E, Van Eijl S and Schinkel AH: Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol 23: 7902-7908, 2003.
26. Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH and Sparreboom A: Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 86: 396-402, 2009.
27. Reifschneider O, Wehe CA, Raj I, Ehmcke J, Ciarimboli G, Sperling M and Karst U: Quantitative bioimaging of platinum in polymer embedded mouse organs using laser ablation ICP-MS. Metallomics 5: 1440-1447, 2013.
28. Ito S, Kusuhara H, Yokochi M, Toyoshima J, Inoue K, Yuasa H, and Sugiyama Y: Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther 340: 393-403, 2012.
29. Katsuda H, Yamashita M, Katsura H, Yu J, Waki Y, Nagata N, Sai Y and Miyamoto K: Protecting Cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity. Biol Pharm Bull 33: 1867-1871, 2010.
30. Sprowl JA, Ciarimboli G, Lancaster CS, Giovinazzo H, Gibson AA, Du G, Janke LJ, Cavaletti G, Shields AF and Sparreboom A: Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci USA 110: 11199-11204, 2013.
31. Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, Chen Y, Komori T, Gray JW, Chen X, Lippard SJ and Giacomini KM: Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 66: 8847-8857, 2006.
32. Yang J, Kalogerou M, Gallacher J, Sampson JR and Shen MH: Renal tumours in a Tsc1+/- mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin. Eur J Cancer 49: 1479-1490, 2013.
33. Schaeffeler E, Hellerbrand C, Nies AT, Winter S, Kruck S, Hofmann U, van der Kuip H, Zanger UM, Koepsell H and Schwab M: DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. Genome Med 3: 82, 2011.
34. Chen L, Hong C, Chen EC, Yee SW, Xu L, Almof EU, Wen C, Fujii K, Johns SJ, Stryke D, Ferrin TE, Simko J, Chen X, Costello JF and Giacomini KM: Genetic and epigenetic regulation of the organic cation transporter 3, SLC22A3. Pharmacogenomics J 13: 110-120, 2013.
35. Sleijfer DT, Offerman JJ, Mulder NH, Verweij M, van der Hem GK, Schraffordt Koops HS and Meijer S: The protective potential of the combination of verapamil and cimetidine on cisplatin-induced nephrotoxicity in man. Cancer 60: 2823-2828, 1987.
36. Zhang J and Zhou W: Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients. Food Chem Toxicol 50: 2289-2293, 2012.